Tempus’ platform builds comprehensive molecular and clinical data sets, leveraging machine learning, sequencing and artificial intelligence-assisted image recognition to offer analysis of and insights into the data.
The company will use the funds to grow operations and expand into new therapeutic areas and geographies.
Additionally, Tempus has collaboration agreements with CancerLinQ, a nonprofit subsidiary of the American Society of Clinical Oncology as well as academic medical centers and National Cancer Institute-designated cancer centers, hospital networks and physicians.
More articles on precision medicine:
Garmin expands work in cardiac health
NIH awards consortium $6.5M to create predictive models for precision medicine
Boston Children’s Hospital to sequence 3K patients’ DNA to study epilepsy, digestive disease
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.